Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria and Symptomatic Dermographism Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex Completes Enrollment in Global Phase 3 Studies of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
EnerCom Opens Registration for the 31st Annual Energy Investment Conference August 17-19, 2026 in Denver, Colorado
QIMC Details Multiple Shallow Hydrogen-Bearing Zones in Drill Hole 26-02 and Advances Integrated Interpretation of Holes 1 and 2; Drill Hole 2 to be Extended to 700 Metres; Drill Mobilized for Hole 3
